Luteinizing hormone-releasing hormone agonists and meningioma: a treatment dilemma - 26/08/11
Abstract |
The relative contraindication of hormonal therapy for patients with prostate cancer and a history of meningioma has not been widely emphasized. Using immunohistochemistry to determine the presence of hormone receptors in meningioma specimens proved potentially valuable in 2 patients with biochemical recurrence after prostatectomy who were being considered for androgen deprivation therapy. These cases also highlight the need for caution against assuming that skull-based intracranial growths in patients receiving hormonal therapy for prostate cancer are metastatic lesions rather than hormonally induced primary tumors.
Le texte complet de cet article est disponible en PDF.Plan
Vol 62 - N° 2
P. 351 - août 2003 Retour au numéro
Article précédent
- Persistent müllerian duct syndrome with crossed testicular ectopia
- Luigi Avolio, Corinne Belville, Romano Bragheri
- Juvenile granulosa cell tumor of the testis
- Randy Fagin, Ema Berbescu, Steve Landis, Kenneth Strumpf, Umeshchandra Patil
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?